Exelixis Inc

EXEL's 15.1% short interest stands out as notably elevated for a biotech name trading at a reasonable 14.2x P/E—well below sector averages. The stock sits firmly neutral on momentum (RSI 46.7) and well below its 52-week high, suggesting limited near-term euphoria despite the substantial short position. This setup hints at underlying skepticism about pipeline prospects or competitive pressures, yet the moderate valuation and short skew create potential squeeze dynamics if clinical or commercial catalysts materialize. The absence of overbought conditions combined with heavy short positioning leaves room for meaningful upside, though the skepticism embedded in that short interest likely reflects legitimate concerns worth investigating before getting excited about the technicals.